FDA Classifies Spinal Muscular Atrophy Newborn Screening Test System as Class II

The Food and Drug Administration has officially classified the Spinal Muscular Atrophy newborn screening test system as a Class II medical device. This classification was finalized in a November 2022 order and codified in the Code of Federal Regulations. It covers the generic category of tests used to screen newborns for SMA by detecting specific genetic mutations in dried blood spot samples.

Why it matters: This is a regulatory classification update that changes how future SMA screening tests are reviewed. It does not approve or ban any specific product, nor does it change current clinical practice. Its main effect is administrative: it lowers the regulatory barrier for competitors by providing a legal predicate, which typically speeds up market entry for similar devices and reduces the paperwork burden for manufacturers.

Who it affects

• Medical device manufacturers developing SMA newborn screening tests

---

This action was issued by the FDA and published in the Federal Register; you should review the full final order and the referenced special controls before relying on the regulatory details.

Agency: Health and Human Services Department, Food and Drug Administration
Source: Federal Register — read the official document